Summit™ and Vantage™, cerebrospinal fluid (CSF) liquid biopsies, displayed a clinically meaningful impact in 82% of central nervous system lymphoma (CNSL) cases, according to findings from a retrospective analysis including 50 CSF samples and 48 patients published in Lymphatics.1
Specifically, the Summit test detected significant variants, by gene level alteration, chromosomal arm level alteration, and/or MGMT promoter methylation per Tier 1 or 2 classification per AMP/ASCO/CAP guidelines, in 32 of 50 samples (64%). Additionally, clinical follow-up of negative cases post-biopsy confirmed 9 of 18 (50%) to be negative, with 2 confirmed as false negatives. The cases impacted by the CSF liquid biopsy tests helped to inform diagnosis, support clinical suspicion of disease progression or recurrence, and confirm…